ECSP067014A - Modulación de producción de inmunoglobulina y trastornos atópicos - Google Patents
Modulación de producción de inmunoglobulina y trastornos atópicosInfo
- Publication number
- ECSP067014A ECSP067014A EC2006007014A ECSP067014A ECSP067014A EC SP067014 A ECSP067014 A EC SP067014A EC 2006007014 A EC2006007014 A EC 2006007014A EC SP067014 A ECSP067014 A EC SP067014A EC SP067014 A ECSP067014 A EC SP067014A
- Authority
- EC
- Ecuador
- Prior art keywords
- modulation
- immunoglobulin production
- atopic disorders
- disorders
- atopic
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Un polipéptido IL-21 u otro agonista de senda IL-21 se pueden utilizar para tratar trastornos atópicos, por ejemplo, asma.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57240704P | 2004-05-19 | 2004-05-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP067014A true ECSP067014A (es) | 2006-12-29 |
Family
ID=35428852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2006007014A ECSP067014A (es) | 2004-05-19 | 2006-11-17 | Modulación de producción de inmunoglobulina y trastornos atópicos |
Country Status (15)
Country | Link |
---|---|
US (1) | US20060024268A1 (es) |
EP (1) | EP1753458A4 (es) |
JP (1) | JP2008501042A (es) |
KR (1) | KR20070014181A (es) |
CN (1) | CN1980698A (es) |
AU (1) | AU2005244942A1 (es) |
BR (1) | BRPI0510996A (es) |
CA (1) | CA2566333A1 (es) |
EC (1) | ECSP067014A (es) |
IL (1) | IL179243A0 (es) |
MX (1) | MXPA06013483A (es) |
NO (1) | NO20065487L (es) |
RU (1) | RU2006138704A (es) |
WO (1) | WO2005112983A2 (es) |
ZA (1) | ZA200609600B (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6057128A (en) | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
US6307024B1 (en) | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
MXPA05000655A (es) | 2002-07-15 | 2006-02-22 | Harvard College | Metodos y composiciones para modular el desarrollo y la funcion de las celulas t helper (th). |
NZ542306A (en) | 2003-03-14 | 2008-04-30 | Wyeth Corp | Antibodies against human IL-21 receptor and uses therefor |
EP1608315A4 (en) * | 2003-03-21 | 2008-07-16 | Wyeth Corp | TREATMENT OF IMMUNOLOGICAL DISORDERS USING INTERLEUKIN-21 / INTERLEUKIN-21 RECEPTOR |
EP1670501A2 (en) * | 2003-09-25 | 2006-06-21 | ZymoGenetics, Inc. | Methods of treating autoimmune diseases using il-21 |
EP2641611A3 (en) * | 2003-10-17 | 2013-12-18 | Novo Nordisk A/S | Combination therapy |
RU2007102287A (ru) * | 2004-08-05 | 2008-09-10 | Вайет (Us) | Антагонисты активности рецептора интерлейкина-21 |
GT200600148A (es) * | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
US8034326B2 (en) * | 2005-04-18 | 2011-10-11 | Novo Nordisk A/S | IL-21 variants |
EP1890723A2 (en) * | 2005-06-06 | 2008-02-27 | Novo Nordisk A/S | Stabilised il-21 compositions |
US7914574B2 (en) * | 2005-08-02 | 2011-03-29 | Reva Medical, Inc. | Axially nested slide and lock expandable device |
EP2567973B1 (en) * | 2005-11-28 | 2014-05-14 | Zymogenetics, Inc. | IL-21 antagonists |
US7592427B2 (en) * | 2005-11-28 | 2009-09-22 | Zymogenetics, Inc. | Antibodies to IL-21 receptor |
US8475784B2 (en) | 2006-10-26 | 2013-07-02 | Novo Nordisk A/S | IL-21 variants |
JP2010512769A (ja) * | 2006-12-21 | 2010-04-30 | ノヴォ ノルディスク アクティーゼルスカブ | Il−21受容体との結合が変化したインターロイキン−21変異体 |
CA2707026C (en) | 2007-12-07 | 2017-04-11 | Zymogenetics, Inc. | Anti-human il-21 monoclonal antibodies |
CA2725154A1 (en) * | 2008-05-23 | 2009-11-26 | Wyeth Llc | Methods of treatment utilizing binding proteins of the interleukin-21 receptor |
AR071885A1 (es) * | 2008-05-23 | 2010-07-21 | Wyeth Corp | Proteinas de union al receptor de interleuquina 21 |
JP2012504939A (ja) * | 2008-09-23 | 2012-03-01 | ワイス・エルエルシー | 架橋結合タンパク質による活性化シグナルの産生を予測するための方法 |
WO2010119307A1 (en) * | 2009-04-14 | 2010-10-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for stimulating antigen-specific t cell responses using accelerated co-cultured dendritic cells |
EP2665486B1 (en) | 2011-01-18 | 2019-12-25 | Bioniz, LLC | Compositions for modulating gamma-c-cytokine activity |
WO2015089217A2 (en) | 2013-12-10 | 2015-06-18 | Bionz, Llc | Methods of developing selective peptide antagonists |
AU2014302028B2 (en) * | 2013-06-27 | 2019-09-19 | Monash University | IL-21 binding proteins and uses thereof |
US10940212B2 (en) | 2014-12-19 | 2021-03-09 | Monash University | IL-21 agonist antibodies and methods of treatment using same |
US11400134B2 (en) | 2015-10-09 | 2022-08-02 | Bioniz, Llc | Modulating gamma-c-cytokine activity |
US11709169B2 (en) * | 2017-02-07 | 2023-07-25 | National Jewish Health | Lipid abnormalities and association with atopic allergic diseases |
CN113874075A (zh) | 2019-05-03 | 2021-12-31 | 比奥尼斯有限责任公司 | 调节γC-细胞因子信号传导对于治疗脱发和脱发相关病症的影响 |
US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US5179017A (en) * | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) * | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4475196A (en) * | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) * | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) * | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4447224A (en) * | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4510245A (en) * | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US4487603A (en) * | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4501728A (en) * | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4486194A (en) * | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US5168062A (en) * | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4596556A (en) * | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US4968615A (en) * | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
US4737323A (en) * | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5116742A (en) * | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
US4987071A (en) * | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
DE3883899T3 (de) * | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
US4941880A (en) * | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) * | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5328470A (en) * | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
EP0470154B1 (en) * | 1989-04-28 | 1996-06-05 | Riker Laboratories, Inc. | Dry powder inhalation device |
US5034413A (en) * | 1989-07-27 | 1991-07-23 | Allergan, Inc. | Intraocular pressure reducing 9,11-diacyl prostaglandins |
US5312335A (en) * | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5383851A (en) * | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5399677A (en) * | 1993-12-07 | 1995-03-21 | Genetics Institute, Inc. | Mutants of bone morphogenetic proteins |
SE9502800D0 (sv) * | 1995-08-10 | 1995-08-10 | Astra Ab | Disposable inhaler |
US20030143204A1 (en) * | 2001-07-27 | 2003-07-31 | Lewis David L. | Inhibition of RNA function by delivery of inhibitors to animal cells |
US7189400B2 (en) * | 1998-03-17 | 2007-03-13 | Genetics Institute, Llc | Methods of treatment with antagonists of MU-1 |
US7198789B2 (en) * | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
US6307024B1 (en) * | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
US20030212022A1 (en) * | 2001-03-23 | 2003-11-13 | Jean-Marie Vogel | Compositions and methods for gene therapy |
ATE349522T1 (de) * | 2000-04-05 | 2007-01-15 | Zymogenetics Inc | Löslicher zytokinrezeptor zalpha11 |
CA2312142A1 (en) * | 2000-06-22 | 2001-12-22 | An-Go-Gen Inc. | Injection system for gene delivery |
ATE444363T1 (de) * | 2001-11-05 | 2009-10-15 | Zymogenetics Inc | Il-21-antagonisten |
US20030166282A1 (en) * | 2002-02-01 | 2003-09-04 | David Brown | High potency siRNAS for reducing the expression of target genes |
US7556944B2 (en) * | 2002-05-03 | 2009-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for use in preparing siRNAs |
JP4339852B2 (ja) * | 2002-08-12 | 2009-10-07 | ニュー・イングランド・バイオラブズ・インコーポレイティッド | 遺伝子サイレンシングに関する方法および組成物 |
MXPA05003729A (es) * | 2002-10-11 | 2005-06-17 | Novo Nordisk As | Tratamiento de condiciones alergicas mediante el uso de il 21. |
NZ542306A (en) * | 2003-03-14 | 2008-04-30 | Wyeth Corp | Antibodies against human IL-21 receptor and uses therefor |
EP1608315A4 (en) * | 2003-03-21 | 2008-07-16 | Wyeth Corp | TREATMENT OF IMMUNOLOGICAL DISORDERS USING INTERLEUKIN-21 / INTERLEUKIN-21 RECEPTOR |
GT200600148A (es) * | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis |
-
2005
- 2005-05-19 JP JP2007527432A patent/JP2008501042A/ja not_active Withdrawn
- 2005-05-19 CN CNA2005800162359A patent/CN1980698A/zh not_active Withdrawn
- 2005-05-19 RU RU2006138704/14A patent/RU2006138704A/ru not_active Application Discontinuation
- 2005-05-19 BR BRPI0510996-5A patent/BRPI0510996A/pt not_active IP Right Cessation
- 2005-05-19 CA CA002566333A patent/CA2566333A1/en not_active Abandoned
- 2005-05-19 MX MXPA06013483A patent/MXPA06013483A/es unknown
- 2005-05-19 KR KR1020067024218A patent/KR20070014181A/ko not_active Application Discontinuation
- 2005-05-19 EP EP05779552A patent/EP1753458A4/en not_active Withdrawn
- 2005-05-19 WO PCT/US2005/017514 patent/WO2005112983A2/en active Application Filing
- 2005-05-19 AU AU2005244942A patent/AU2005244942A1/en not_active Withdrawn
- 2005-05-19 US US11/132,947 patent/US20060024268A1/en not_active Abandoned
-
2006
- 2006-11-13 IL IL179243A patent/IL179243A0/en unknown
- 2006-11-17 ZA ZA200609600A patent/ZA200609600B/xx unknown
- 2006-11-17 EC EC2006007014A patent/ECSP067014A/es unknown
- 2006-11-28 NO NO20065487A patent/NO20065487L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ZA200609600B (en) | 2010-04-28 |
CN1980698A (zh) | 2007-06-13 |
RU2006138704A (ru) | 2008-06-27 |
NO20065487L (no) | 2006-12-18 |
AU2005244942A1 (en) | 2005-12-01 |
IL179243A0 (en) | 2007-03-08 |
WO2005112983A3 (en) | 2006-10-05 |
BRPI0510996A (pt) | 2007-12-04 |
EP1753458A2 (en) | 2007-02-21 |
EP1753458A4 (en) | 2009-07-22 |
WO2005112983A2 (en) | 2005-12-01 |
CA2566333A1 (en) | 2005-12-01 |
MXPA06013483A (es) | 2007-01-23 |
KR20070014181A (ko) | 2007-01-31 |
JP2008501042A (ja) | 2008-01-17 |
US20060024268A1 (en) | 2006-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP067014A (es) | Modulación de producción de inmunoglobulina y trastornos atópicos | |
NL301145I2 (nl) | Tirbanibulin | |
UA101478C2 (ru) | Соединения, полезные как ингибиторы raf-киназы | |
TW200732349A (en) | Anti-OX40L antibodies and methods using same | |
MXPA06012796A (es) | Ciertas entidades quimicas, composiciones y metodos. | |
WO2011022489A3 (en) | (bis) urea and (bis) thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders | |
DK1866414T3 (da) | Inhibitorer af ribonukleotidreduktase-underenhed 2 og anvendelser deraf. | |
NO20082305L (no) | Mikrobiologisk stabilisert ol | |
ATE518010T1 (de) | Aktive oberflächengekoppelte polymerasen | |
ATE544774T1 (de) | Rnai-modulation von mll-af4 und verwendungen dafür | |
WO2007002376A3 (en) | Method of preparing electrode | |
MX2009008104A (es) | Hepcidina, antagonistas de hepcidina y metodos de uso. | |
GEP20094623B (en) | Heteroaromatic quinoline compounds and their use as pde10 inhibitors | |
WO2006127768A3 (en) | Microscale micropatterned engineered in vitor tissue | |
ATE473744T1 (de) | Modifizierte pyrimidin-glucocorticoid-rezeptor- modulatoren | |
WO2006023866A3 (en) | Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1 | |
MX2007015427A (es) | Inhibidores de azinona y diazinona v3 para depresion y trastornos de estres. | |
WO2007056143A3 (en) | Certain chemical entities, compositions, and methods | |
NO20073368L (no) | Amid-promedikament av gemcitabin, sammensetninger og anvendelse derav | |
MX2008001538A (es) | Aril piridinas y metodos para su uso. | |
ATE542536T1 (de) | 3-ä4-(dibenzoäb,füä1,4üoxazepin-11-yl)-piperazi - 1-ylü-2,2-dimethyl propansäure zur verwendung in der behandlung von schlafstörungen | |
MX2010002028A (es) | Metodos y composiciones para modular celulas t. | |
WO2007056469A3 (en) | Certain chemical entities, compositions, and methods | |
MY173526A (en) | Novel anti-?5?1 antibodies and uses thereof | |
MX2010001657A (es) | Reguladores de mmp-9 y usos de los mismos. |